P76. 10 Erlotinib Plus Anlotinib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: An Open-Label, Phase 2 Study
T Chu, W Zhang, B Zhang, R Zhong, C Shi… - Journal of Thoracic …, 2021 - jto.org
Methods In this open-label, phase 2 study, NSCLC patients with previously untreated, EGFR
mutation (exon 19 deletion or L858R) received anlotinib (10 mg QD from day 1 to 14 of a 21-
day cycle) and erlotinib (at a dose of 150 mg once daily) until disease progression or
treatment intolerance. The primary outcome was objective response (ORR) and secondary
outcomes were PFS, disease control rate (DCR) and overall survival (OS). Results A total of
60 patients were enrolled from October 2018 to November 2019. Among these patients, 35 …
mutation (exon 19 deletion or L858R) received anlotinib (10 mg QD from day 1 to 14 of a 21-
day cycle) and erlotinib (at a dose of 150 mg once daily) until disease progression or
treatment intolerance. The primary outcome was objective response (ORR) and secondary
outcomes were PFS, disease control rate (DCR) and overall survival (OS). Results A total of
60 patients were enrolled from October 2018 to November 2019. Among these patients, 35 …
以上显示的是最相近的搜索结果。 查看全部搜索结果